# A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct05943795/  
OnCo record `nct05943795` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SI-B001 and docetaxel in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active but no longer recruiting.

## Summary

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma is a phase 3, randomised interventional study registered as NCT05943795 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 589 participants, started 2023-07-14 and due to reach its primary completion in 2026-07. Interventions recorded: SI-B001; Docetaxel. Conditions listed: Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung. Primary outcome: Overall survival (OS); Progression-free survival (PFS). Lung eligibility wording from the registry: "Patients with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05943795
- Phase: 3
- Setting: A Phase III Clinical Study of SI-B001 Combined With Docetaxel Second-line Therapy in Patients With Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Without Actionable Genomic Alterations Who Failed Only First-line Treatment With PD-1/PD-L1 Monoclonal Antibody Plus Platinum-Based Chemotherapy
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 589

## Sources

- ClinicalTrials.gov NCT05943795: https://clinicaltrials.gov/study/NCT05943795

## Connected records

- cancers: [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [SI-B001](https://onco.cc/drugs/si-b001/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05943795.json